{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:25:51Z","timestamp":1788582351989,"version":"build-2803163510"},"reference-count":49,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Currently, no established marker exists for predicting peritoneal metastasis progression during chemotherapy, although they are major interruptive factors in sequential chemotherapy in patients with advanced gastric cancer (AGC). This multicenter retrospective study was conducted from June 2015 to July 2019, analyzing 73 patients with AGC who underwent taxane-plus-ramucirumab (TAX\/RAM) therapy and had their serum carbohydrate antigen 125 (CA125) concentrations measured. Of 31 patients with elevated CA125 levels above a cutoff of 35 U\/mL, 25 (80.6%) had peritoneal metastasis. The CA125 concentrations before TAX\/RAM treatment were associated with ascites burden. The overall survival was significantly shorter in the CA125-elevated group. CA125 kinetics, measured at a median of 28 days after chemotherapy, were associated with the ascites response (complete or partial response: \u22121.86%\/day; stable disease: 0.28%\/day; progressive disease: 2.33%\/day). Progression-free survival in the CA125-increased group, defined by an increase of 0.0067%\/day using receiver operating characteristic curve analysis, was significantly poorer among patients with peritoneal metastases. In conclusion, this study highlights that CA125 kinetics can serve as an early predictor for the progression of peritoneal metastasis during TAX\/RAM treatment.<\/jats:p>","DOI":"10.3390\/cancers16050871","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T11:28:47Z","timestamp":1708601327000},"page":"871","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer"],"prefix":"10.3390","volume":"16","author":[{"given":"Akira","family":"Ueda","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Kita14, Nishi 5, Kita-ku, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, University of Miyazaki Hospital, 5200 Kihara, Kiyotake-cho, Miyazaki 889-1692, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naokatsu","family":"Nakada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Itoigawa Sogo Hospital, 457-1 Takegahana, Itoigawa 941-8502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ishikawa Prefectural Central Hospital, 2-1 Kuratuki Higashi, Kanazawa 920-8530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Motoo","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tomakomai City Hospital, 1-5-20 Shimizucho, Tomakomai 053-8567, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Sakumura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, University of Miyazaki Hospital, 5200 Kihara, Kiyotake-cho, Miyazaki 889-1692, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Kita14, Nishi 5, Kita-ku, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-0015","authenticated-orcid":false,"given":"Yasuyuki","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Division of Cancer Center, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-6802","authenticated-orcid":false,"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Division of Cancer Center, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060-8648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6888-0310","authenticated-orcid":false,"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association (2023). Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer, 26, 1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Niclauss, N., G\u00fctgemann, I., Dohmen, J., Kalff, J.C., and Lingohr, P. (2021). Novel biomarkers of gastric adenocarcinoma: Current research and future perspectives. Cancers, 13.","DOI":"10.3390\/cancers13225660"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jjco\/hyx044","article-title":"Survival after failure of first-line chemotherapy in advanced gastric cancer patients: Differences between Japan and the rest of the world","volume":"47","author":"Takashima","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00280-018-3569-9","article-title":"Survival impact of post-progression chemotherapy in advanced gastric cancer: Systematic review and meta-analysis","volume":"81","author":"Iizumi","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12325-021-01931-3","article-title":"Treatment pattern for advanced gastric cancer in Japan and factors associated with sequential treatment: A retrospective administrative claims database study","volume":"39","author":"Komatsu","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000526577","article-title":"Factors, including clinical trial eligibility, associated with induction of third-line treatment for advanced gastric cancer","volume":"101","author":"Ando","year":"2023","journal-title":"Oncology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10120-011-0128-z","article-title":"Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil\/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer","volume":"15","author":"Cho","year":"2012","journal-title":"Gastric Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10120-011-0056-y","article-title":"First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer","volume":"15","author":"Iwasa","year":"2012","journal-title":"Gastric Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10147-017-1198-7","article-title":"First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake","volume":"23","author":"Hara","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Matsumoto, H., Kawazoe, A., Shimada, K., Fukuoka, S., Kuboki, Y., Bando, H., Kojima, T., Ohtsu, A., Yoshino, T., and Doi, T. (2018). A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4057-7"},{"key":"ref_21","first-page":"5169","article-title":"Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: Symptom\/tumor marker-based versus CT-based","volume":"34","author":"Hasegawa","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.3748\/wjg.v21.i39.10936","article-title":"Evaluation and treatment of malignant ascites secondary to gastric cancer","volume":"21","author":"Maeda","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jjco\/29.11.550","article-title":"Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer","volume":"29","author":"Yamao","year":"1999","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/02841860802446761","article-title":"Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer","volume":"48","author":"Kim","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10120-011-0091-8","article-title":"Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination","volume":"15","author":"Emoto","year":"2012","journal-title":"Gastric Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","article-title":"Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G)","volume":"23","author":"Nakajima","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5230\/jgc.2017.17.e16","article-title":"Prognostic factor analysis of overall survival in gastric cancer from two Phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data","volume":"17","author":"Fuchs","year":"2017","journal-title":"J. Gastric Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10120-017-0702-0","article-title":"Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials","volume":"20","author":"Takahari","year":"2017","journal-title":"Gastric Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the Phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_31","first-page":"1645","article-title":"An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer","volume":"24","author":"Berglund","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41416-020-0901-z","article-title":"Prognostic significance of pre- and post-operative tumour markers for patients with gastric cancer","volume":"123","author":"Lin","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/PL00011715","article-title":"Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer","volume":"3","author":"Kochi","year":"2000","journal-title":"Gastric Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10120-003-0240-9","article-title":"The usefulness of CEA and\/or CA19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study","volume":"6","author":"Takahashi","year":"2003","journal-title":"Gastric Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10120-006-0360-0","article-title":"Follow-up of gastric cancer: A review","volume":"9","author":"Whiting","year":"2006","journal-title":"Gastric Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1245\/s10434-018-6634-z","article-title":"Preoperative tumor markers independently predict survival in Stage III gastric cancer patients: Should we include tumor markers in AJCC staging?","volume":"25","author":"Lin","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Haque, E., Esmail, A., Muhsen, I., Salah, H., and Abdelrahim, M. (2022). Recent trends and advancements in the diagnosis and management of gastric cancer. Cancers, 14.","DOI":"10.3390\/cancers14225615"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-2002-33228","article-title":"Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer","volume":"34","author":"Fujimura","year":"2002","journal-title":"Endoscopy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/onc.2010.87","article-title":"Membrane-bound mucins: The mechanistic basis for alterations in the growth and survival of cancer cells","volume":"29","author":"Bafna","year":"2010","journal-title":"Oncogene"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1158\/1078-0432.CCR-04-2236","article-title":"Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm","volume":"11","author":"Dennis","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Amroun, K., Chaltiel, R., Reyal, F., Kianmanesh, R., Savoye, A.M., Perrier, M., Djerada, Z., and Bouch\u00e9, O. (2022). Dynamic prediction of resectability for patients with advanced ovarian cancer undergoing neo-adjuvant chemotherapy: Application of joint model for longitudinal CA-125 levels. Cancers, 15.","DOI":"10.3390\/cancers15010231"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e6884","DOI":"10.1097\/MD.0000000000006884","article-title":"Third-line chemotherapy in advanced gastric cancer: A systematic review and meta-analysis","volume":"96","author":"Zheng","year":"2017","journal-title":"Medicine"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Alsina, M., Tabernero, J., and Diez, M. (2022). Chemorefractory gastric cancer: The evolving terrain of third-line therapy and beyond. Cancers, 14.","DOI":"10.3390\/cancers14061408"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zhou, Q., Wang, H., Zhuo, W., Ding, Y., Lu, J., Wu, G., Xu, N., and Teng, L. (2020). Predicting peritoneal dissemination of gastric cancer in the era of precision medicine: Molecular characterization and biomarkers. Cancers, 12.","DOI":"10.3390\/cancers12082236"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3892\/mco.2015.510","article-title":"Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy","volume":"3","author":"Hamamoto","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"International, B.R. (2023). Retracted: Levels and significance of tumor markers and cytokines in serum and peritoneal lavage fluid of patients with peritoneal metastasis of gastric cancer. Biomed Res. Int., 2023.","DOI":"10.1155\/2023\/9892635"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2147\/CMAR.S193739","article-title":"Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data","volume":"11","author":"Muro","year":"2019","journal-title":"Cancer Manag. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/871\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:50Z","timestamp":1760104970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16050871"],"URL":"https:\/\/doi.org\/10.3390\/cancers16050871","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}